Skip to main content

Table 6 In vitro cytotoxicity (IC50Μ)a data of compounds (9a-j) [30]

From: Therapeutic potential of oxadiazole or furadiazole containing compounds

Compound A549bc MCF-7d A375e HT-29f
9a 1.20 ± 0.16 0.098 ± 0.004 2.56 ± 0.36 0.012 ± 0.001
9b 0.023 ± 0.006 0.011 ± 0.001 1.90 ± 0.71
9c 2.30 ± 0.21 2.19 ± 0.28 8.30 ± 1.60
9d 3.56 ± 0.19 2.11 ± 0.23 6.13 ± 1.12 7.14 ± 0.86
9e 5.02 ± 1.02 12.4 ± 0.96
9f 0.27 ± 0.02 1.07 ± 0.59 2.81 ± 0.25 1.55 ± 0.65
9 g 0.013 ± 0.001 0.80 ± 0.15 1.05 ± 0.53 1.24 ± 0.17
9 h 1.02 ± 0.50 0.010 ± 0.004 1.99 ± 0.29 3.78 ± 0.16
9i 13.9 ± 0.54 18.50 ± 0.86 8.23 ± 1.35
9j 0.90 ± 0.09 0.12 ± 0.01 0.39 ± 0.012 1.10 ± 0.54
Combretastatin-A4 0.11 ± 0.01 0.18 ± 0.01 0.21 ± 0.02 0.93 ± 0.03
  1. aEach data represented as mean ± S.D values. From three different experiments performed in triplicates, bcA549: Human lung cancer cell line, dMCF-7: Human breast cancer cell line, eA375: Human melanoma cancer cell line, fHT-29: Human colon cancer cell line. –: Not active